Owner of Paradigm Peptides Sentenced to Prison for Fraudulent Practices

A federal judge sentenced Matthew Kawa, owner of Paradigm Peptides, to nearly six years in prison. He was found guilty of deceiving customers and selling products adulterated with steroids. Kawa pleaded guilty last year to selling unapproved drugs and importing them illegally. His case highlights the largely unregulated market of peptide sales labeled ‘for research use.’

Sentencing and Impact

U.S. District Court Judge Cristal Brisco sentenced Kawa to 70 months, emphasizing his focus on profit over customer safety. “You focused on what you wanted to build instead of thinking about the people,” she stated. The business had 54,000 unique customers in the U.S. and 80 countries. Kawa agreed to forfeit $5 million in proceeds.

Wearing a gray suit, Kawa expressed regret, acknowledging that customers relied on deceitful statements. “I’m deeply sorry I betrayed that trust,” he told the court. Kawa declined to comment further to CBS News.

Deceptive Practices

Paradigm Peptides advertised its products as American-made, 99% pure, and tested by third-party labs. These claims were false. Paradigm imported products from China, India, and other countries. Kawa admitted to forging laboratory certificates. Government tests revealed compounds contained actual testosterone, regulated due to health risks.

Paradigm claimed its products were for research only, but Kawa admitted they were marketed for human consumption. His sister, Jennifer Stechkober, was sentenced to 16 months in prison for her integral role in the operation.

Market and Effects

Peptides, chains of amino acids, have become popular for weight loss, muscle gain, and longevity. Their use is growing despite lacking FDA approval. Licensed physicians prescribe them. There is a trend toward mainstream acceptance.

Paradigm also sold SARMs (selective androgen receptor modulators), linked to severe side effects like heart attacks and psychosis. Paradigm labeled them as dietary supplements, misleading some customers about their safety.

“I would hope it’s a wake-up call for a lot of the other research-use-only companies out there because this is actual prison time,” said attorney David Holt.

Case of Dan Murphy

Dan Murphy, a 32-year-old, took SARMs from Paradigm in 2023, thinking they were safe. He experienced increased energy, but later developed severe side effects like paranoia and cystic acne. He received a letter from the Department of Justice about the investigation into Paradigm.

Upon testing, a SARM he purchased tested positive for testosterone. Murphy was diagnosed with “steroid-induced psychosis.” He is suing Paradigm Peptides, which Kawa is contesting.

Industry Impact

Legal experts are uncertain about the lasting impact of Kawa’s sentencing. Health officials like Robert F. Kennedy Jr. promote peptides’ benefits. Discussions to broaden access to peptides, including BPC-157, continue.

Even after Paradigm’s closure, new websites with similar names and labels continue selling similar products. A new site denied affiliation with Kawa, claiming it would redesign any concerning labels.